These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 17458039

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Effect of non-calcium-based phosphate binders on vascular calcifications in patients on hemodialysis: clinical experience and hypotheses].
    Bolasco P.
    G Ital Nefrol; 2011; 28(4):357. PubMed ID: 21809303
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
    Cozzolino M, Brancaccio D.
    Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
    Hashimoto N, Miyata M, Sato N, Mochizuki T, Koike T.
    Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Experience with sevelamer in peritoneal dialysis].
    Ortiz A, Ríos F, Melero R, Reyero A, Gazapo R, Casado S.
    Nefrologia; 2003 Sep; 23(5):432-6. PubMed ID: 14658169
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
    Al-Baaj F, Speake M, Hutchison AJ.
    Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Phosphorus (P) chelant in dialysis: efficacy and cost. Peritoneal dialysis solutions].
    Montenegro J.
    Nefrologia; 2008 Apr; 28 Suppl 5():53-7. PubMed ID: 18847421
    [Abstract] [Full Text] [Related]

  • 39. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
    Altmann P, Barnett ME, Finn WF, SPD405-307 Lanthanum Carbonate Study Group.
    Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
    [Abstract] [Full Text] [Related]

  • 40. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN, Dialysis Clinical Outcomes Revisited Investigators.
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.